A key innovation lies in the design of dual- and trispecific antibodies that engage multiple tumor antigens (e.g., BCMA/GPRC5D/CD3 or BCMA/CD3/CD28), thereby mitigating antigen escape and incorporating intrinsic co-stimulatory signaling to sustain T cell activation [77,78,79,80]. The gene discussed is CD28; the disease is neoplasm.